List of Excipients in Branded Drug FLUDEOXYGLUCOSE

Generic Drugs Containing FLUDEOXYGLUCOSE

Company	Ingredient	NDC	Excipient
Biomedical Research Foundation of Northwest Louisiana	fludeoxyglucose f-18	24562-001	SODIUM CHLORIDE
Biomedical Research Foundation of Northwest Louisiana	fludeoxyglucose f-18	24562-001	SODIUM CITRATE
The University of Texas MD Anderson Cancer Center	fludeoxyglucose f18	60215-411	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in FLUDEOXYGLUCOSE?

# Of NDCs	Excipient
4	SODIUM CHLORIDE
4	SODIUM CITRATE

Fludeoxyglucose F 18 Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Fludeoxyglucose F 18, commonly called FDG or 18F-FDG, is a short-lived PET radiopharmaceutical used primarily for oncology imaging and for selected cardiac and neurologic indications. Its excipient profile is intentionally simple: sterile water, sodium chloride for isotonicity, and, depending on the product and process, a small amount of buffering or stabilizing material. Commercial value is concentrated less in the active ingredient than in reliable radiochemistry, low-metal manufacturing, sterile delivery systems, regional distribution, and validated quality-control infrastructure.

What is the formulation of fludeoxyglucose F 18 injection?

FDG is an aqueous intravenous solution of 2-deoxy-2-[18F]fluoro-D-glucose. The fluorine-18 isotope has a physical half-life of approximately 109.8 minutes, which drives the formulation, manufacturing, packaging, and distribution model.[1]

Formulation attribute	Commercial relevance
Active ingredient	2-deoxy-2-[18F]fluoro-D-glucose
Dosage form	Sterile intravenous injection
Route	Intravenous
Typical vehicle	Sterile water for injection
Tonicity agent	Sodium chloride, commonly used to produce an approximately isotonic solution
Preservatives	Generally avoided because of intravenous use, radiopharmaceutical quality requirements, and short product life
Container	Shielded multidose or unit-dose vial, syringe, or automated dispensing system
Radioisotope	Fluorine-18
Half-life	Approximately 109.8 minutes
Primary quality risks	Radionuclidic identity, radiochemical purity, chemical impurities, sterility, endotoxin, residual solvents, pH, and radioactive concentration

FDA-approved FDG labeling describes the product as a sterile, clear, colorless solution for intravenous administration. Product-specific excipient concentrations and pH ranges should be taken from the applicable FDA-approved labeling and Chemistry, Manufacturing, and Controls documentation rather than inferred from the generic name.[2]

Why is FDG’s excipient burden low?

FDG does not require a solubilizing system comparable to that used for poorly water-soluble small molecules. The labeled molecule is sufficiently water-compatible for injection, and the product is administered at relatively small volumes. The principal formulation objectives are:

1. Maintaining sterility and acceptable endotoxin levels.
2. Preserving radiochemical purity during the product’s short shelf life.
3. Achieving suitable pH and tonicity.
4. Minimizing chemical and radioactive degradation.
5. Avoiding excipients that interfere with PET quantification, patient safety, or regulatory release.

The formulation must remain compatible with automated synthesis modules, sterile filtration, shielded containers, dose calibrators, and patient-administration systems.

What excipients are commercially relevant for FDG?

The strongest excipient opportunities are low-volume, high-specification materials that address radiolysis, metal contamination, isotonicity, or container compatibility.

Sodium chloride and isotonicity control

Sodium chloride is the most straightforward formulation component. It can support isotonicity and improve injection tolerability. The commercial opportunity is limited for commodity sodium chloride but more attractive for pharmaceutical-grade, low-endotoxin, low-metal raw materials packaged for radiopharmaceutical production.

Supplier differentiation can involve:

• Lot-to-lot control of trace metals.
• Low endotoxin and bioburden specifications.
• Compatibility with automated synthesis equipment.
• Sterile, single-use packaging.
• Documentation suitable for 21 CFR Part 212 manufacturing.
• Rapid regional distribution to radiopharmacies.

Buffer systems

Some FDG processes use buffering to control pH. Buffer selection must account for radiochemical stability, intravenous safety, precursor impurities, metal ions, and compatibility with the synthesis pathway.

Potential buffer systems must be assessed for:

• Impact on radiochemical purity.
• Interaction with residual fluoride or metallic contaminants.
• Sterile filtration performance.
• Stability over the product’s short release window.
• Effect on assay, pH, and PET image quality.
• Compatibility with the final container and administration device.

A buffer that improves stability but creates a new impurity profile may reduce commercial value. In practice, a low-excipient formulation that consistently meets release specifications can be more valuable than a chemically elaborate formulation.

Radiolysis stabilizers

Ionizing radiation can generate reactive species that affect radiochemical purity. Stabilizers such as ascorbate or related antioxidant systems may have a role in selected radiopharmaceutical formulations, but their use in FDG must be justified through product-specific stability and safety data.

The commercial opportunity is not simply to add an antioxidant. A viable stabilizer platform must demonstrate:

• Improved end-of-shelf-life radiochemical purity.
• No adverse impact on glucose metabolism or PET interpretation.
• No interference with sterility or endotoxin testing.
• Compatibility with the synthesis and purification system.
• Acceptable toxicological and regulatory status.
• Repeatable performance at low concentration.

Stabilizers are most commercially attractive in situations involving longer transport distances, higher radioactive concentrations, delayed administration, or multi-dose pharmacy operations.

Low-metal excipient systems

Trace metals can affect radiochemistry and may contribute to variability in fluorination, purification, or degradation. Low-metal excipient grades and low-extractable-contact materials can therefore have greater value than standard pharmaceutical grades.

Commercial products may include:

• Low-metal sodium chloride solutions.
• Chelator-compatible process fluids.
• Low-extractable tubing and filter assemblies.
• Metal-controlled buffers.
• Prequalified single-use synthesis consumables.

This opportunity sits at the boundary between excipients, process materials, and manufacturing equipment.

How does fluorine-18 change the FDG commercial model?

FDG is not distributed like a conventional tablet or long-half-life injectable. Fluorine-18 decays rapidly, requiring production close to the imaging site or an efficient regional distribution network.

Local and regional production

Most FDG is manufactured in cyclotron-equipped facilities or radiopharmacies. The short half-life limits the economic radius of distribution. Commercial providers compete on:

• Cyclotron uptime.
• Synthesis yield.
• Batch consistency.
• Release-test speed.
• Delivery route density.
• Dose scheduling.
• Waste reduction.
• Backup production capacity.

Excipient suppliers can capture value by integrating their products into validated synthesis kits, automated cassettes, or standardized production platforms. A formulation component that reduces process variability has more commercial value than a low-cost commodity excipient.

Multidose and unit-dose packaging

FDG may be supplied in multidose containers or prepared as unit doses. The packaging system must provide radiation shielding while supporting aseptic withdrawal and accurate dose measurement.

Relevant commercial products include:

• Shielded vials.
• Tungsten or lead syringe shields.
• Low-extractable elastomeric closures.
• Automated dose-dispensing systems.
• Closed transfer devices.
• Sterile single-use tubing sets.
• Radioactive-waste containment systems.

The container-closure system is a significant part of product performance. Extractables, adsorption, septum puncture behavior, sterility assurance, and dose recovery can affect both regulatory approval and pharmacy economics.

What FDA regulatory requirements apply to FDG excipients?

FDG manufacturing is subject to radiopharmaceutical-specific requirements under FDA regulations, including 21 CFR Part 212 for PET drugs.[3] FDA guidance also addresses PET drug production, quality systems, release testing, and production controls.[4]

Excipient and process-material qualification generally must support:

• Identity and quality of each raw material.
• Supplier qualification.
• Control of bioburden and endotoxin.
• Sterility assurance.
• Chemical and radiochemical purity.
• Residual solvent control.
• pH and osmolality.
• Container-closure integrity.
• Stability through the labeled expiration period.
• Compatibility with the synthesis and purification process.

The United States Pharmacopeia provides relevant standards for radiopharmaceutical preparation and quality systems, including general chapters addressing radiopharmaceuticals and sterile compounding.[5] The applicable standard depends on whether the activity involves commercial manufacturing, PET drug production, hospital preparation, or pharmacy compounding.

Does every excipient require a new FDA approval?

A change to an excipient or its concentration can require regulatory assessment even when the excipient is widely used in injectable products. The regulatory effect depends on the product’s approved formulation, manufacturing process, specifications, and filing pathway.

A change can trigger:

• CMC comparability work.
• Additional stability studies.
• Process validation.
• New extractables and leachables assessment.
• Revised release specifications.
• Supplement or amendment activity.
• New documentation for an abbreviated or commercial PET drug application.

The key issue is not whether the material is generally recognized as safe. The issue is whether the material performs consistently in the specific radioactive, sterile, short-lived product system.

What patents protect fludeoxyglucose and its excipients?

The original composition and use concepts for FDG are old and generally outside meaningful commercial exclusivity in the United States. FDG’s commercial protection is therefore more likely to arise from manufacturing know-how, proprietary synthesis systems, equipment integration, quality-control methods, and operational scale than from an active composition patent covering the molecule itself.

Orange Book status

FDG products approved under PET drug pathways do not generally depend on a conventional active-ingredient patent estate. Orange Book-listed patent coverage, if present for a particular product, must be evaluated by product-specific application number and current FDA listing. The central commercial barrier is usually not an Orange Book patent but the ability to produce and release a sterile dose before substantial radioactive decay.

Formulation and process patents

Potentially relevant patent categories include:

• Stabilized radiopharmaceutical formulations.
• Automated FDG synthesis methods.
• Fluorination and deprotection processes.
• Purification systems.
• Cartridge and cassette designs.
• Low-metal reaction vessels.
• Dose-dispensing and delivery systems.
• Methods for reducing radiolysis.
• Quality-control methods for rapid release.
• Integrated cyclotron and synthesis platforms.

These rights may provide stronger practical protection than a basic FDG formulation patent, particularly when they are embedded in validated manufacturing workflows. Their value depends on claim scope, freedom to operate, geographic coverage, and whether the process is visible in the final product.

Are Paragraph IV challenges or biosimilar risks relevant to FDG?

Paragraph IV challenges

Paragraph IV litigation is generally less central to FDG than to conventional small-molecule drugs with substantial patent-protected sales. A generic-drug-style challenge could arise if a marketed FDG product had relevant listed patents, but the commercial economics are constrained by local manufacturing, short shelf life, and the limited value of duplicating a basic aqueous formulation.

Competitive entry is more likely to occur through:

• A separate PET drug application.
• A manufacturing-site approval.
• A radiopharmacy expansion.
• A contract manufacturing arrangement.
• A new synthesis platform.
• Regional supply agreements.

Biosimilar risk

Biosimilars are not relevant to FDG. FDG is a chemically defined small molecule labeled with a radioactive isotope, not a biologic. The relevant competitive risks are generic-style duplication, compounded PET drug production, alternate radiopharmacy supply, and improvements in manufacturing efficiency.

Which companies compete in the FDG market?

Competition includes multinational radiopharmaceutical companies, hospital-based radiopharmacies, cyclotron operators, contract manufacturers, and equipment suppliers. Large participants have included Cardinal Health, Curium, Jubilant Radiopharma, Siemens Healthineers, and regional PET drug producers, although market participation varies by country and facility.

The competitive landscape is local because supply depends on:

• Cyclotron location.
• Regulatory approvals.
• Transport time.
• Production capacity.
• Hospital contracts.
• Reimbursement.
• Access to PET scanners.
• Backup supply arrangements.

A company does not need a novel FDG molecule to win market share. It can compete through dependable early-morning production, delivery accuracy, low rejected-dose rates, and coverage of underserved imaging centers.

What are the highest-value commercial opportunities in FDG excipients?

Excipient and consumable opportunities

Opportunity	Commercial rationale	Main barrier
Low-metal sodium chloride and buffer systems	Reduces process variability and supports qualification	Commodity pricing
Radiolysis stabilizers	May extend usable shelf life or improve transport reliability	Need product-specific proof
Sterile synthesis cassettes	Locks in workflow and recurring consumable revenue	Validation and platform dependence
Low-extractable vials and closures	Protects purity and dose recovery	Packaging qualification
Shielded unit-dose systems	Improves pharmacy safety and labor efficiency	Equipment capital cost
Rapid QC consumables	Reduces release time and decay-related waste	Method validation
Single-use sterile fluid paths	Supports aseptic processing and standardization	Disposal and supply continuity
Contract FDG manufacturing	Expands regional coverage without new hospital infrastructure	Transport and regulatory compliance

Revenue exposure

FDG revenue is sensitive to dose wastage. A production failure or delayed delivery can destroy the commercial value of a batch because the isotope continues to decay regardless of whether the dose is administered. Suppliers that reduce failed batches, release delays, residual activity, or rejected doses can participate in value that exceeds the excipient’s unit price.

The strongest commercial model combines a specialized material with a recurring service or platform relationship. Examples include prequalified consumable kits, annual supply contracts, equipment-service agreements, and process-optimization services.

How strong is the patent estate for FDG compared with newer PET drugs?

FDG has a weak composition-patent position but a durable manufacturing market. Newer PET agents may have stronger composition, method-of-use, formulation, and manufacturing patents. FDG remains commercially resilient because it has broad clinical adoption, established reimbursement pathways, extensive physician familiarity, and a large installed PET infrastructure.

Factor	FDG	Newer PET tracer
Composition patent strength	Generally low	Often moderate to high during exclusivity
Manufacturing complexity	Moderate	Frequently higher
Distribution constraint	Severe due to F-18 half-life	Depends on isotope
Clinical adoption	Broad	Indication-specific
Excipient differentiation	Limited but practical	Potentially broader
Litigation exposure	Usually limited	Can be substantial
Commercial moat	Supply network and execution	Patents, clinical data, and supply network

What generic launch risks exist for FDG?

A competing FDG supplier can enter without overcoming a major molecule patent, but entry still requires:

• An approved or otherwise authorized PET drug pathway.
• Cyclotron and synthesis capability.
• Validated sterile production.
• Qualified personnel.
• Rapid quality-control testing.
• Radiation-safety infrastructure.
• Reliable delivery routes.
• Hospital and imaging-center contracts.

The most credible launch strategy is regional. A new supplier can target markets where incumbent supply is unreliable, delivery distances are long, or PET scanner capacity is expanding. A national launch is less efficient because FDG economics favor distributed production.

Key Takeaways

• FDG is a short-lived PET radiopharmaceutical whose formulation is usually simple and aqueous.
• Sodium chloride, sterile water, buffers, radiolysis stabilizers, low-metal raw materials, and container systems are the principal excipient-related opportunities.
• The most valuable innovations reduce batch failure, radioactive decay loss, release delays, or dose wastage.
• FDG has limited practical composition-patent protection compared with newer PET tracers.
• Commercial barriers arise from cyclotron access, sterile manufacturing, quality control, transport, and hospital distribution.
• Paragraph IV and biosimilar risks are limited or inapplicable; competition is primarily operational and regional.
• The strongest business models combine specialized excipients with synthesis cassettes, sterile consumables, packaging, QC systems, or contract radiopharmacy services.

FAQs

Can FDG be formulated with preservatives?

Preservatives are generally unattractive for FDG because the product is an intravenous radiopharmaceutical with a short shelf life and strict sterility, endotoxin, and compatibility requirements. Any preservative would require product-specific safety and stability justification.

Does FDG require an antioxidant excipient?

Not universally. An antioxidant may be useful in a specific manufacturing or transport configuration, but its benefit must be demonstrated through radiochemical stability data, process compatibility, and clinical-quality specifications.

Can excipient suppliers patent an FDG formulation?

A supplier may seek protection for a novel stabilized formulation, excipient combination, container system, or manufacturing process. A basic FDG-in-water formulation is unlikely to provide strong new patent protection because the core formulation concept is longstanding.

Why are FDG manufacturing cassettes commercially important?

Cassettes standardize fluid paths, reduce setup time, support aseptic processing, and can become integral to an automated synthesis platform. Their recurring-use model can produce more defensible revenue than sales of commodity excipients.

Is FDG suitable for centralized national manufacturing?

Only to a limited extent. Fluorine-18’s approximately 109.8-minute half-life favors local or regional production. Centralized manufacturing is feasible where transport networks, production timing, and dose scheduling support delivery before excessive radioactive decay.

References

1. International Atomic Energy Agency. (2009). Cyclotron produced radionuclides: Principles and practice. IAEA.
2. U.S. Food and Drug Administration. (n.d.). Fludeoxyglucose F 18 injection prescribing information. FDA.
3. Code of Federal Regulations. (2024). 21 C.F.R. Part 212: Current good manufacturing practice for positron emission tomography drugs.
4. U.S. Food and Drug Administration. (2009). PET drugs: Current good manufacturing practice; small entity compliance guide. FDA.
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters on radiopharmaceuticals and sterile preparations. USP.